Jubira 5 Tablet contains Rosuvastatin 5 mg, a potent HMG-CoA reductase inhibitor used primarily for the management of hyperlipidemia and the prevention of cardiovascular disease. Rosuvastatin works by inhibiting the enzyme responsible for cholesterol biosynthesis in the liver, leading to a significant reduction in low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, while modestly increasing high-density lipoprotein cholesterol (HDL-C). This lipid-lowering effect helps reduce the risk of atherosclerosis, coronary artery disease, stroke, and other cardiovascular events. Jubira 5 is indicated for patients with primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia, as well as for those requiring secondary prevention of cardiovascular disease. The recommended dosage should be individualized based on the patient’s lipid profile, therapeutic goals, and tolerability. Common adverse effects include headache, myalgia, abdominal pain, and nausea, while rare but serious side effects such as myopathy and hepatotoxicity require monitoring of liver enzymes and creatine kinase levels during therapy. Jubira 5 should be used with caution in patients with pre-existing liver or kidney impairment and is contraindicated during pregnancy and lactation. Lifestyle modifications including diet, exercise, and weight control should accompany pharmacotherapy for optimal results.